To further explore the therapeutic value of TNFR2 in demyelinating diseases, we investigated the impact of a single intracerebroventricular (i.c.v.)injection of human TNFR2 agonist EHD2-scTNFR2 into the brain on remyelination in the cuprizone mouse model following demyelination. The gene discussed is TNFRSF1B; the disease is demyelinating disease.